Emblation is an award-winning medical technology company, revolutionising the way microwave energy is used in healthcare.
Its aim is to improve on traditional treatments using the unique advantages microwaves deliver – accurate, repeatable procedures, and better clinical outcomes.
Emblation’s technology is transforming the treatment of HPV infections globally. Its Swift® System is widely used in Dermatology, Podiatry, and Oncology, with a number of disruptive applications under development in associated fields of medicine.
The Swift® treatment works by delivering a highly controlled dose of energy into the tissue, which creates heat and stimulates an immune response. This reduces the risks associated with destructive modalities, and results in highly effective outcomes for stubborn skin lesions.
The company was started in 2007 by joint co-founders Gary Beale and Eamon McErlean (Chief Executive Officer and Chief Technology Officer), the inventors behind the technology. They form part of the management team, with over 50 years of experience in this field.
Emblation’s medical devices can be found in 1000s of clinics and hospitals across the UK, US, Canada, Australia, and New Zealand and the company is headquartered in central Scotland.